secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641489-25-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026
--------------------------------------------------------------------------------

- Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.
- Cash at March 31, 2025: $31.1M, down from $36.7M at December 31, 2024.
- Revenue was $0 compared to $1.0M in the prior-year period.
- Phase 3 CATT1 trial for cadisegliatin shortened from 12 to 6 months; topline data expected in 2H 2026.
- R&D expenses $2.8M, G&A $3.7M; operating loss of $6.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/0001641489-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/vtvt-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer